RNLXYRenalytix plc

About Renalytix plc (RNLXY)

Renalytix plc (RNLXY) is a Health Information Services company headquartered in Salt Lake City, UT, United States whose shares trade over-the-counter on the OTCQB tier.

Renalytix is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage chronic kidney disease (CKD) (stages 1-3b) risk assessment for progressive decline in kidney function in type-2 diabetes patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs

Products and services

KidneyIntelX.dkd prognostic test offered through physicians and healthcare providers.

RNLXY key facts

Ticker symbol

RNLXY

Market tier

OTCQB

Sector

Healthcare

Industry

Health Information Services

Headquarters

Salt Lake City, UT, United States

Country of incorporation

GB

Year of incorporation

2018

Employees

35

Estimated market cap

$2.65M (as of Apr 10, 2025)

Shares outstanding

25,192,403

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

6/30

Latest filing

Semi-Annual Report (Dec 31, 2024)

Renalytix plc leadership

• James McCullough — CEO
• Howard Doran — President
• Joel Jung — CFO
• Michael J Donovan — CMO
• Fergus Fleming — CTO
• Paul Martin Anthony McManus — Advisor
• Dominic O'Brien — Controller
• Alice Woodings — IR

Explore more: Health Information Services stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with R